Novavax Valuation
| 0A3S Stock | 11.90 2.90 32.22% |
At this time, the firm appears to be overvalued. Novavax secures a last-minute Real Value of USD10.0 per share. The latest price of the firm is USD11.9. Our model forecasts the value of Novavax from analyzing the firm fundamentals such as Return On Equity of -8.98, profit margin of (0.32) %, and Current Valuation of 789.75 M as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 789.7 M |
Overvalued
Today
Please note that Novavax's price fluctuation is very risky at this time. Calculation of the real value of Novavax is based on 3 months time horizon. Increasing Novavax's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novavax stock is determined by what a typical buyer is willing to pay for full or partial control of Novavax. Since Novavax is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novavax Stock. However, Novavax's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 11.9 | Real 10.0 | Hype 16.02 | Naive 9.4 |
The intrinsic value of Novavax's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novavax's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novavax helps investors to forecast how Novavax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novavax more accurately as focusing exclusively on Novavax's fundamentals will not take into account other important factors: Novavax Total Value Analysis
Novavax is presently projected to have takeover price of 789.75 M with market capitalization of 789.75 M, debt of , and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novavax fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
789.75 M | 789.75 M |
Novavax Investor Information
About 60.0% of the company shares are owned by institutions such as pension funds. The company recorded a loss per share of 17.51. Novavax had not issued any dividends in recent years. The entity had 0.05:1 split on the 10th of May 2019. Based on the key measurements obtained from Novavax's financial statements, Novavax is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.Novavax Asset Utilization
One of the ways to look at asset utilization of Novavax is to check how much profit was generated for every dollar of assets it reports. Novavax secures a negative usage of assets of -0.11 %, losing USD0.001076 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Novavax shows how discouraging it operates for each dollar spent on its assets.Novavax Profitability Analysis
The company reported the revenue of 885.19 M. Net Loss for the year was (657.94 M) with profit before overhead, payroll, taxes, and interest of 115.46 M.About Novavax Valuation
The stock valuation mechanism determines Novavax's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Novavax based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novavax. We calculate exposure to Novavax's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novavax's related companies.Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.